Φορτώνει......
In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site
Mutations in isocitrate dehydrogenase 1 (IDH1) are found in 6% of AML patients. Mutant IDH produces R-2-hydroxyglutarate (R2HG), which induces histone- and DNA-hypermethylation through inhibition of epigenetic regulators, thus linking metabolism to tumorigenesis. Here we report the biochemical chara...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Leukemia |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6995692/ https://ncbi.nlm.nih.gov/pubmed/31586149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-019-0582-x |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|